In summary, our studies show that a 2HF–PLO gel is active when applied topically to cutaneous melanoma, that the mechanism of action appears to be through Rlip protein depletion, and that it may enhance the anticancer effects of sunitinib and PARP1 inhibitor. The gene discussed is RALBP1; the disease is cutaneous melanoma.